leadf
logo-loader
viewSahel Oncology

Sahel Oncology using technology to battle aggressive cancers like lung and ovarian

sahe

Sahel Oncology CEO Michael A Nezami talked to Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. The drug developer is focused on oncology, with key products that have shown promising results in variety of cancer types. The company's main aim is to apply therapies that improve overall survival, rather than tumor size or progression free survival.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Mandalay Resources latest drilling shows impressive results from Youle...

Mandalay Resources (TSE: MND-OTCQB: MNDJF) President and CEO Dominic Duffy joined Steve Darling from Proactive with news the company has seen some very strong numbers from the latest drill results on the Youle Deposit at their Costerfield Project. Duffy telling Proactive the numbers returned...

1 day, 4 hours ago

2 min read